JW Asset Management Trims Liquidia Stake

JW Asset Management reduced its stake in Liquidia Corporation, a biotech firm focused on pulmonary hypertension treatments. This comes after Liquidia saw a significant increase in share price and strong sales for its product, YUTREPIA, indicating a strategic profit-taking move…

Listen